Enabling better health by maximising access to important medicines




Pharmaceutical and Biotech clients


Healthcare Professional customers

Providing access to medicines

Clinigen exists to provide quicker and broader access to critical medicines around the world. In the last three years Clinigen have provided access to medicines into 128 countries around the globe, 66 of which were developing countries and a further 12 transitioning countries where there are challenges in gaining access to critical medicines.

Clinigen currently provide access to more than 1,400 medicines through our Managed Access, Partnered and On-Demand channels. We also support access of medicines into hundreds of pharma led and physician led clinical trials through the clinical services function, meaning the portfolio of medicines we provide enables access for patients in clinical studies, unlicensed markets and licensed markets.

Clinigen also work with closely with our pharma partners to provide solutions that enable them to fulfil their ESG goals of providing broader access to their medicines. In the last 12 months we have partnered with 577 pharma and biotech companies to facilitate better access to medicines.

Clinigen currently have more than 25,000 healthcare professionals registered as users on our online platform Cliniport, of which more than 6,000 where added in the past 12 months.

Patient focused

It is vital that the solutions we provide put the patients’ needs first and so throughout the year we have remained focused on patientcentric solutions and offerings.

We continue to provide Direct-to- Patient services through our clinical services and in 2021 we also joined the Decentralised Trials and Research Alliance (‘DTRA’). The DTRA consists of an alliance of life sciences and healthcare companies that seeks to accelerate the broad adoption of patient-focused, decentralised clinical trials and research.

It is estimated that clinical trials may be set back by several years in the context of COVID-19, due to prospective patients’ inability or reluctance to schedule visits at physical research locations. Decentralized approaches to conducting research facilitate participation by a more diverse patient population and could ease COVID- 19-imposed difficulties for both patients and clinical investigators.

In FY2021 the Group also rolled out the Patient Advocate Fellowship in early access, an initiative aimed at equipping patient groups and their leadership with the skills and experience they need to engage meaningfully within early access.